@nlinmd

Breast cancer specialist @DanaFarber; Director, EMBRACE MBC program. Tweets are my own and not medical advice.

Joined December 2016
  • Tweets687
  • Following390
  • Followers3.6K
93Media
🔥 Good news for TNBC patients with brain mets! Dato-DXd shows clinically meaningful activity in BMs ⚠️ Caveat: small TB02 subgroup, only half with active BMs (asymptomatic, untreated) 👉 Key message: after T-DXd, Dato-DXd also shows clear intracranial activity #ESMO26
6
1
25
1,080
Nancy Lin, MD retweeted
Ilana Schlam@IlanaSchlamOct 9
One more week to complete our survey! We want to understand what clinicians need to bring ctDNA MRD testing into routine clinical practice. If you care for patients with breast cancer, please take a few minutes to participate and help shape future research! @nlinmd @stolaney1
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOncOct 9
Dr. Ilana Schlam (@IlanaSchlam) discussing her new #ctDNA study at the HCC #BreastCancerResearchRetreat. The study is on the use of ctDNA NGS and MRD Assays in Clinical Practice. If you are a licensed clinician who treats patients with #BreastCancer, help us better understand current practice patterns and perceptions regarding the use of circulating tumor DNA (ctDNA) standard next-generation sequencing (#NGS) assays and minimal residual disease (#MRD) assays in breast cancer, across both early-stage and metastatic settings. 👉Study Link: redcap.link/ctdna_provider
6
12
1,500
Yes! Pts w/MBC need: -HER2+: effective tx post TDXD esp that treat/prevent brain mets TNBC: effective tx post Trop2 x topo1 ADC. ADC are “better chemo” but we need game changers that transform the tail of the OS curve ER+: options after 1L chemo when OS really starts to fall
Dr Sarah Sammons
@drsarahsamSep 24
Our immense desire to move every successful therapy in metastatic breast cancer to front line is stifling innovation. Also the “me too” mentality of every company buying the same drug is a challenge. Hi from the clinic, We need new targets, new payloads, new 2L and 3L options in TNBC and HeR2+ MBC!
6
4
28
3,259
10 new @FDA indications in #bcsm in 20 weeks - May to September, 2026. Three firsts in there: first PROTAC in any cancer, first CDK4/6 inhibitor in HER2+ #bcsm, first drug approval triggered by ctDNA prior radiographic progression. #clinicaltrials win! Patients win!
4
42
4
89
13,126
I have really enjoyed working with Wassim on novel liquid biopsy technologies!
Wassim Daoud Khatoun@WDKhatounSep 22
Hi #MedTwitter! Excited to be applying to #InternalMedicine for #Match2027! 🩺 I’m a @lebamericanuni #IMG from 🇱🇧, currently a research fellow studying cancer epigenomics & liquid biopsy @DanaFarber @harvardmed. AAMC ID: 14999066 Grateful for everyone who made this possible!
1
1
7
2,165
Very cool approach leveraging LLM to characterize toxicity and correlate with GWAS at a scale that allows discovery of novel associations!
Sasha Gusev
@SashaGusevPostsSep 18
Tour de force characterizing therapy toxicity in cancer at very large scale!
7
902
Grateful for the growing options to treat ESR1-mutated tumors. This combination was NCCN endorsed and now FDA approved. This pace of progress is exciting for our patients — but our work is far from done! @MSKCancerCenter @OncoAlert #bcsm
Oncology Brothers
@OncBrothersSep 18
Imlunestrant + Abema now @FDA ✅ based off EMBER-3: Ph III, #Imlunestrant +/-#Abemaciclib in HR+ mESR1 advanced BC! - Imlunestrant alone for mESR1 approved. - Combo⬆️ mPFS w/all comers (11.1mos vs 5.5mos) - If co-PIK3CA, Capi or this combo? #bcsm #OncTwitter @OncUpdates
1
15
40
3,471
📣We are leading a study on the use of #ctDNA NGS and MRD Assays in Clinical Practice. If you are a licensed clinician who treats patients with #BreastCancer, help us better understand current practice patterns and perceptions regarding the use of circulating tumor DNA (ctDNA) standard next-generation sequencing (#NGS) assays and minimal residual disease (#MRD) assays in breast cancer, across both early-stage and metastatic settings. Our goal is to identify how these tools are currently being used, the perceived barriers to their implementation, and the evidence or resources needed to support the integration of ctDNA testing into routine clinical practice. Thank you in advance for taking our short (10-15 minutes) questionnaire! 👉Link: redcap.link/ctdna_provider For more info: [email protected] #BreastCancerResearch #BloodTest #BloodBiopsy PI: Ilana Schlam (@IlanaSchlam)
8
17
1,584
Brilliant keynote from @HendriksLizza - ‘Breaking Barriers, Redefining Brain Metastases Treatment Concepts” at #snoasco2026 -identifying pts at high risk -optimizing tx and sequencing -access- trials, molecular testing, drugs, knowledge -multiD teamwork and collaborations
2
3
1
18
1,660
Nancy Lin, MD retweeted
SNO@NeuroOncAug 14
We are looking forward to a full day of dynamic presentations and discussions at this year’s SNO/ASCO CNS Metastases Conference. Co-chairs Jona Hattangadi-Gluth and Jarushka Naidoo kick-off the “From Moonshot to Groundshot: Transforming Science into Impact” meeting. #SNOASCO2026
1
2
552
Join the EMBRACE Program for a day of wellness, education, and community building! Hosted in collaboration with Dana-Farber’s Zakim Center for Integrative Therapies and Healthy Living, this free event will include tai chi, massage, ear acupuncture, expressive arts, mindful movement, and more. Open to adults living with #MetastaticBreastCancer and their loved ones. #MBC 🗓️ Wednesday, September 9 | 10 a.m. - 3:30 p.m. ET 📍 Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA Register today ➡️ redcapdfci.dfci.harvard.edu/…
4
4
1,097
Such a beautiful story. Gleevec made the impossible possible. I remember the moment when people with CML no longer filled our bone marrow transplant units, because a small pill transformed their lives. The power of science + humanity + clinical trials. ❤️🙏
Mel Mann, MBA, M.Ed
@MelDMannAug 8
31 years ago I was diagnosed with terminal #cancer. No cure. Three years to live. I recruited many thousands of potential bone marrow donors, but never found one for myself. My daughter was 5 years old when I was diagnosed. Because of a miracle, I was able to see her grow up, go to #Harvard & become a board certified physician. In 2015 I shared my clinical trial miracle story. That one post hit 7 million impressions. I’m still here. The World’s longest-living #Gleevec survivor. Clinical trials rewrote my ending. Original post: xitter.cf/MelDMann/status/656937… Share if you know someone who needs this hope today! ❤️ #CML #ClinicalTrials #CancerSurvivor
1
5
16
1,644
Nancy Lin, MD retweeted
Sara Tolaney@stolaney1Aug 7
Team Duncan is truly amazing!! Congrats to the team, and thank you for all the support for breast oncology research!! It means so much to the work we can do to try + improve patient outcomes! @DFCI_BreastOnc @PhilipPoorvu
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOncAug 6
Congratulations to Dr. Phil Poorvu (@PhilipPoorvu) and Team Duncan on completing the @PanMass Challenge bike-a-thon last weekend and raising $1.1 million for #BreastCancer research!
1
6
27
2,903
📢 Social and support opportunities for adults diagnosed with stage IV metastatic breast cancer under the age of 45 Whether you are interested in connecting with other young adults who “get it” from time to time or building a new network of support, EMBRACing Young and Strong socials are a great way to meet and connect with others who were diagnosed under the age of 45. 📅 Thursdays | 6:30 – 7:45 PM ET ➤ July 30: Cooking Demo ➤ Aug 20: Lymph Flow Yoga 🔗 To learn more and register, please visit: redcapdfci.dfci.harvard.edu/…
10
10
1,081
ZN1041: ➡️Oral HER2 selective TKI ➡️>100x penetration across intact BBB vs tucatinib ➡️ ++activity combined with TDXd or maintenance HP ➡️ph 2/3 BREnnA study just launched (ZN/cape/tras vs tuca/cape/tras). Pts w/ or w/o brain mets and LMD eligible! clinicaltrials.gov/study/NCT…
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOncJun 1
#ASCO26 Poster Session | Poster #169 | Safety and efficacy of ZN-A-1041, a highly blood-brain barrier-permeable HER2 tyrosine kinase inhibitor (#TKI), + trastuzumab deruxtecan (#TDXd) or pertuzumab-trastuzumab in HER-positive metastatic breast cancer (HER2+ #mBC): Phase Ic expansion results from the ZN-A-1041-101-US trial. @nlinmd
2
18
1
42
6,483
OPTIMA: N=4429 Age 40+ ER >10% 0-9 nodes (19% N2) 37% premen - all received OFS ➡️ No diff in invasive events in control (chemo-ET for all) vs prosigna directed tx allocation (~2/3 of pts spared chemo) ➡️ No meaningful benefit of chemo in ROR<60 including premen or N2 subsets
6
1
11
1,370
Beautiful, moving remarks and call to action from Dr. Eric Small @ASCOPres. To all we have lost, family members and patients, we love you, we miss you, and it is our deepest privilege to honor your memory in the present.
4
23
1,318
I wish Felix were still here to see all the incredible advances at ASCO this year. I miss his irrepressible energy so much. Let us support @ConquerCancerFd with a CDA to extend his legacy. Link below 👇
Toni Choueiri, MD
@DrChoueiriMay 30
Over a year ago we lost Felix, a giant in Cancer research to ….Cancer. Let us support @ASCO with a CDA in the honor of Dr Feng. support.conquer.org/p2p/site… #ASCO26 @OncoAlert @ConquerCancerFd
11
36
3,533
The best part of #ASCO26 for me!
Mary Feng@MaryFengMDMay 30
Besides hearing about cutting edge science and discussing trials at #ASCO26, love catching up with friends including my bestie and sister @nlinmd
1
17
1,025
Sarah - you are an incredible person. Thank you for everything, especially your inspired and vibrant leadership of the EMBRACE program which has supported so many people living with MBC. This is not goodbye - I look forward to our friendship and collaborations continuing
Dr Sarah Sammons
@drsarahsamMay 15
Today is my last day at Dana-Farber Cancer Institute. 💙🎗️ DFCI is a place unlike any other. The standard of care, culture of intellectual curiosity, the relentless focus on patients. A special thank you to Dr. Sara Tolaney and Dr. Nancy Lin for your gracious mentorship. There is no better place. Our hearts are full. We’re heading home to family. 💙 Soon I’m joining the @UMGCCC University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center as Co-Leader of Breast Oncology, with a deep commitment to growing the breast program for the people of Baltimore and the DMV. We plan to initiate a new multidisciplinary CNS Metastases Clinic, home to Maryland’s only Proton Center. 🧠⚡ @UMGCCC is one of 56 NCI-designated comprehensive cancer centers in the country, moving into a brand new state-of-the-art building, and on the rise under the visionary leadership of Dr. Taofeek Owonikoko. To every patient who trusted me: thank you and you are in the best hands. 🎗️ #BreastCancer #Baltimore #BrainMetastases #ProtonTherapy #Oncology #NewChapter #UMGCCC
2
15
1,035
Load more